|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 346.75 USD | -1.23% |
|
+3.86% | +14.13% |
| 13/01 | BeOne Medicines AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 07:30 AM | |
| 08/01 | RBC Raises Price Target on BeOne Medicines to $417 From $408, Keeps Outperform Rating | MT |
| Capitalization | 3.84TCr 3.29TCr 3.07TCr 2.85TCr 5.32TCr 3,46400Cr 5.74TCr 35TCr 14TCr 1,65700Cr 14TCr 14TCr 6,07200Cr | P/E ratio 2025 * |
106x | P/E ratio 2026 * | 52.9x |
|---|---|---|---|---|---|
| Enterprise value | 3.6TCr 3.09TCr 2.88TCr 2.68TCr 5TCr 3,25300Cr 5.39TCr 33TCr 13TCr 1,55600Cr 14TCr 13TCr 5,70200Cr | EV / Sales 2025 * |
6.8x | EV / Sales 2026 * | 5.5x |
| Free-Float |
96.17% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BeOne Medicines AG
| 1 day | -1.23% | ||
| 1 week | +3.86% | ||
| Current month | +14.13% | ||
| 1 month | +8.68% | ||
| 3 months | +8.04% | ||
| 6 months | +37.52% | ||
| Current year | +14.13% |
| 1 week | 328.74 |  | 353.1 |
| 1 month | 299.5 | | 353.1 |
| Current year | 304.78 | | 353.1 |
| 1 year | 196.45 | | 385.22 |
| 3 years | 126.97 | | 385.22 |
| 5 years | 118.18 | | 426.56 |
| 10 years | 22.51 | | 426.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Oyler
CEO | Chief Executive Officer | 57 | 28/10/2010 |
Xiao Bin Wu
PSD | President | 64 | 01/04/2018 |
Aaron Rosenberg
DFI | Director of Finance/CFO | 50 | 22/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
John Oyler
CHM | Chairman | 57 | 27/01/2016 |
Michael Goller
BRD | Director/Board Member | 51 | 01/04/2015 |
Ranjeev Krishana
BRD | Director/Board Member | 52 | 01/10/2014 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23% | +3.86% | +72.52% | +28.11% | 3.84TCr | |
| +0.93% | +1.81% | +3.27% | +11.91% | 4.9TCr | |
| -0.09% | -1.20% | +21.92% | +8.65% | 4.11TCr | |
| -4.30% | +0.24% | +19.22% | +36.66% | 3.16TCr | |
| +1.06% | +18.02% | +204.34% | +302.86% | 2.34TCr | |
| +1.32% | +0.55% | +86.29% | +169.71% | 1.74TCr | |
| +8.08% | -33.49% | +27,398.05% | +4,371.14% | 1.74TCr | |
| -0.42% | +4.18% | +54.81% | +10.54% | 1.48TCr | |
| +0.81% | -8.94% | -7.73% | -17.69% | 1.41TCr | |
| +1.06% | +1.89% | +65.17% | +88.92% | 1.33TCr | |
| Average | +0.73% | -1.41% | +2,791.79% | +501.08% | 2.61TCr | |
| Weighted average by Cap. | +0.26% | -0.14% | +1,875.80% | +346.66% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 529.58Cr 454.43Cr 423.11Cr 393.74Cr 734.76Cr 48TCr 792.09Cr 4.86TCr 1.91TCr 23TCr 1.99TCr 1.95TCr 84TCr | 643.43Cr 552.12Cr 514.07Cr 478.39Cr 892.72Cr 58TCr 962.37Cr 5.91TCr 2.33TCr 28TCr 2.41TCr 2.36TCr 1,01800Cr |
| Net income | 33Cr 29Cr 27Cr 25Cr 46Cr 3.01TCr 50Cr 306.31Cr 120.5Cr 1.44TCr 125.06Cr 122.48Cr 5.28TCr | 71Cr 61Cr 57Cr 53Cr 98Cr 6.4TCr 106Cr 651.02Cr 256.11Cr 3.06TCr 265.8Cr 260.32Cr 11TCr |
| Net Debt | -233.63Cr -200.48Cr -186.66Cr -173.7Cr -324.15Cr -21TCr -349.44Cr -2.15TCr -844.26Cr -10TCr -876.2Cr -858.14Cr -37TCr | -296.18Cr -254.15Cr -236.63Cr -220.21Cr -410.93Cr -27TCr -442.99Cr -2.72TCr -1.07TCr -13TCr -1.11TCr -1.09TCr -47TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | 346.75 $ | -1.23% | 2,87,595 |
| 13/26/13 | 351.06 $ | +5.11% | 3,59,695 |
| 12/26/12 | 333.99 $ | -1.15% | 5,37,720 |
| 09/26/09 | 337.89 $ | +5.47% | 6,66,561 |
| 08/26/08 | 320.37 $ | -4.04% | 4,19,244 |
Delayed Quote Nasdaq, January 15, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ONC Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition